Literature DB >> 34561739

A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.

Yujing Xin1, Xinyuan Zhang1, Ying Li1, Yi Yang1, Yi Chen1,2, Yanan Wang1, Xiang Zhou3, Xiao Li1.   

Abstract

OBJECTIVE: To explore the prognostic value of the systemic inflammation response index (SIRI) defined as neutrophil count × monocyte count/lymphocyte count in the patients with early stage hepatocellular carcinoma (HCC) within the Milan criteria after radiofrequency ablation (RFA).
MATERIALS AND METHODS: The prognostic value of SIRI was evaluated in a primary cohort (n = 403) and then further validated in an independent test cohort (n = 140). A novel preoperative prognostic nomogram was constructed from a multivariate analysis and validated in an external validation cohort.
RESULTS: The optimal cutoff value of SIRI for patient stratification into a low SIRI group and a high SIRI group was 1.36. Survival analysis showed that the median overall survival (OS) and recurrence-free survival (RFS) were significantly higher in patients with a low SIRI compared to those with a high SIRI. The alpha-fetoprotein (AFP), SIRI, tumor number and size were independent predictors of RFS based on multivariate analysis. The nomogram including the SIRI, tumor number, tumor size, AFP could more accurately determine the prognosis of HCC patients than BCLC stage (0.74 vs. 0.62, P < 0.001). In addition, the dynamic changes in post-RFA SIRI also had prognostic significance and patients with a reduction in the SIRI by > 75% had a better prognosis.
CONCLUSION: Preoperative SIRI was an independent predictor for RFS in patients with early stage HCC within the Milan criteria. The comprehensive nomogram can objectively and reliably help clinicians identify high-risk patients and develop individualized treatment plans.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Entities:  

Keywords:  Hepatocellular carcinoma; Radiofrequency ablation; Recurrence-free survival; Systemic inflammation response index

Mesh:

Year:  2021        PMID: 34561739     DOI: 10.1007/s00270-021-02965-4

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  [Resistance of the blood vessels of the conjunctiva in nearsightedness and emmetropia during the course of pregnancy and after labor].

Authors:  V V Ivanov
Journal:  Vestn Oftalmol       Date:  1973

2.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

3.  Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis.

Authors:  Yuan Chen; Ming Jin; Yingjie Shao; Guoping Xu
Journal:  Dis Markers       Date:  2019-11-04       Impact factor: 3.434

  3 in total
  2 in total

1.  Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Kangning Han; Dongmei Shi; Lixia Yang; Zhijian Wang; Yueping Li; Fei Gao; Yuyang Liu; Xiaoteng Ma; Yujie Zhou
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Commentary on: Embolization of the Transhepatic Tract After Percutaneous Portal Vein Interventions: Single-Centre Retrospective Study Comparing n-butyl Cyanoacrylate Versus Coils.

Authors:  Mohammad Arabi
Journal:  Cardiovasc Intervent Radiol       Date:  2021-09-24       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.